Brief: Shandong Boan Biotechnology Says Dulaglutide Injection Approved For Marketing By Nmpa
08/08/2025 11:31
Aug 8 (Reuters) - Shandong Boan Biotechnology 6955.HK: DULAGLUTIDE INJECTION (BOYOUPING) APPROVED FOR MARKETING IN CHINA BY NMPA Further company coverage: 6955.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil